|
1) http://www/mhlw.go.jp/shingi/2003/08/s0806-4.htm
|
|
|
|
|
2) Okuno A, Tamemoto H, Tobe K, et al. Troglitazone increase the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest. 1998; 101: 1343-61
|
|
|
|
|
3) Auwerx J. PPARγ, the ultimate thrifty gene. Diabetologia. 1999; 42: 1033-49
|
|
|
|
|
4) Kubota N, Terauchi Y, Miki H, et al. PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell. 1999; 4: 597-609
|
|
|
|
|
|
5) Kadowaki T, Yamauchi T, Kubota N, et al. Adiponection and adiponectin receptor in insulin resistance, diabetes and metabolic syndrome. J Clin Invest. 2006; 116: 1784-92
|
|
|
|
|
|
6) Chen Z, Ishibashi S, Perrey S, et al. Troglitazone inhibits atherosclerosis in apolipoprotein E- knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol. 2001; 21: 372-7
|
|
|
|
|
|
7) Li AC, Brown KK, Silvestre MJ, et al. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000; 106: 523-31
|
|
|
|
|
|
8) Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356: 2457-71
|
|
|
|
|
|
9) Durbin RJ. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab. 2004; 6: 280-5
|
|
|
|
|
|
10) UK Prospective Diabetes Study (UKPDS) group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34). Lancet. 1998; 352: 854-65
|
|
|
|
|
|
11) The Diabetes Control and Complications Trial research group. The Effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977-86
|
|
|
|
|
|
12) Matsuji J, Terauchi Y, Kubota N, et al. Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferators-activeted receptor-γ-deficient mice on a high-fat diet. Diabetes. 2004; 53: 2844-54
|
|
|
|
|
|
13) Kawasaki F, Matsuda M, Kanda Y, et al. Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice. Am J Physiol Endocrinol Metab. 2005; 288: E510-8
|
|
|
|
|
|
14) Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2, 445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007; 49: 1772-80
|
|
|
|
|
|
15) Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342: 145-53
|
|
|
|
|
|
16) Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003; 362: 759-66
|
|
|
|
|
|
17) Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364: 685-96
|
|
|
|
|
|
18) Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial. Lancet. 1998; 351: 1755-62
|
|
|
|
|
|
19) Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007; 38: 865-73
|
|
|
|
|
|
20) Sacco RL, Benson RT, Kargman DE, et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA. 2001; 285: 2729-35
|
|
|
|
|
|
21) Robert S, et al. Effect of long-term Treatment with pioglitazone on Lipid Levels in Patient Receiving Statin Therapy at Baseline in the PROactive study. ADA scientific sessions, 2007
|
|
|
|
|
|
22) Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006; 296: 2572- 81
|
|
|
|
|
|
23) Touboul PJ, Elbaz A, Koller C, et al. Common carotid artery intima-media thickness and brain infarction: the Etude du Profil Genetique de l'Infarctus Cerebral (GENIC) case-control study. The GENIC Investigators. Circulation. 2000; 102: 313-8
|
|
|
|
|
|
24) Bierwirth R, et al. Pioglitazone lowers the intima-media-thickness (IMT) in patients with type-2-diabetes mellitus. ADA scientific sessions, 2007
|
|
|
|
|
|
25) Gerstein HC, Yusuf S, Bosch J, et al: DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006; 368: 1096-105
|
|
|
|
|
|
26) Knowler WC, Barrett-Connor E, Fowler SE, et al: Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346: 393-403
|
|
|
|
|
|
27) Ramachandran A, Snehalatha C, Mary S, et al. Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006; 49: 289-97
|
|
|
|
|
|
28) Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355: 2427-43
|
|
|
|
|
|
29) Kawamori R, et al. PRACTICAL study; Updated efficacy and safety in 23000 Japanese Type 2 Patients. ADA scientific sessions, 2005
|
|
|
|
|
|
30) Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006; 355: 2297-307
|
|
|
|
|
|
31) http://www.jdoit3.jp
|
|
|
|
|